Anika Therapeutics | ANIK - Equity Capital And Reserves


Anika Therapeutics reported $143.46M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Abbott USD 52.13B 1.3B Dec/2025
Agenus USD -271.11M 3.03M Dec/2025
Agios Pharmaceuticals USD 1.19B 91.22M Dec/2025
Anika Therapeutics USD 143.46M 3.34M Dec/2025
Arrowhead Research USD 568.42M 102.37M Dec/2025
Enanta Pharmaceuticals USD 126.59M 61.87M Dec/2025
Halozyme Therapeutics USD 48.81M 455.1M Dec/2025
Heron Therapeutics USD 13.28M 1.6M Dec/2025
Insmed USD 738.98M 206.6M Dec/2025
Integra LifeSciences USD 1.04B 5.89M Dec/2025
Intrexon USD 43.17M 75.33M Jun/2024
J&J USD 81.54B 3.07B Dec/2025
Karyopharm Therapeutics USD -292.93M 23.67M Dec/2025
Ligand Pharmaceuticals USD 1.02B 67.04M Dec/2025
MacroGenics USD 55.59M 11.41M Dec/2025
Merit Medical Systems USD 1.58B 54.9M Dec/2025
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sanofi EUR 71.71B 1.55B Dec/2025
Smith & Nephew USD 5.54B 331M Dec/2025
Stryker USD 21.78B 594M Sep/2025
Surmodics USD 111.31M 7.59M Jun/2025
Veracyte USD 1.26B 36.61M Sep/2025
Xencor USD 635.59M 10.27M Dec/2025
Zimmer Biomet Holdings USD 12.7B 68.3M Dec/2025